Victoria Forster, PhD

Victoria Forster is a postdoctoral research scientist and freelance science writer. Her research interests include; DNA repair deficiencies, pediatric cancers, stem cell and organoid models for cancer development and cancer treatment-related side effects. She is also a 25-year survivor of childhood leukemia and an advocate for childhood cancer awareness. She has bylines in several outlets including The Times, The Guardian, Forbes, and Cancer Therapy Advisor.

All articles by Victoria Forster, PhD

A new review points to low rates of genetic testing in patients with ovarian cancer.

Gynecologic Cancer

Universal Genetic Testing Is Far From a Reality in Patients With Ovarian Cancer

Victoria Forster, PhD

June 8, 2021

A new review points to low rates of genetic testing in patients with ovarian cancer.

A 10% reduction in calorie intake during the first month of treatment shows promise for augmenting chemotherapy treatment in children and adolescents with ALL.

Hematologic Cancers

Caloric Reduction Improves Outcomes for Young People With Acute Lymphoblastic Leukemia

Victoria Forster, PhD

May 10, 2021

A 10% reduction in calorie intake during the first month of treatment shows promise for augmenting chemotherapy treatment in children and adolescents with ALL.

A comprehensive review provides clinical pearls and approaches to consider regarding chemoradiotherapy for patients with stage III non-small cell lung cancer.

Lung Cancer

Radical Therapy for Stage III NSCLC: Practical Advice to Consider

Victoria Forster, PhD

May 7, 2021

A comprehensive review provides clinical pearls and approaches to consider regarding chemoradiotherapy for patients with stage III non-small cell lung cancer.

Pediatric Cancer

Socioeconomics Tied to Cognitive Function in Survivors of Childhood Brain Tumors

Victoria Forster, PhD

April 8, 2021

Researchers hope their findings could lead to targeted interventions to improve cognitive outcomes in pediatric brain tumor survivors from families with low socioeconomic status.

Multiple Myeloma

Therapeutic Approaches to Multiple Myeloma: An Interview With Ajai Chari, MD

Victoria Forster, PhD

April 2, 2021

Ajai Chari, MD, of Mount Sinai Hospital in New York City, provides his perspective on the current state of care in multiple myeloma.

Photobiomodulation shows impressive results in pretrial use for treatment and prevention of treatment-associated mucositis in pediatric patients.

Pediatric Cancer

Light-Based Therapy Shows Promise in Treating Mucositis in Pediatric Cancer Patients

Victoria Forster, PhD

March 9, 2021

Photobiomodulation shows impressive results in pretrial use for treatment and prevention of treatment-associated mucositis in pediatric patients.

Rarely, patients with prostate cancer will develop metastases to the gastrointestinal tract, which l

ASCO GI 2021

OS Benefit Modest or Absent With Many High-Cost Therapies Approved for GI Malignancies

Victoria Forster, PhD

January 27, 2021

Investigators assessed disparities in patient access to therapies approved for the treatment of gastrointestinal malignancies in the United States, the United Kingdom, Europe, and Ireland, as well as benefit relative to cost.

liver affected by cirrhosis and hepatitis

ASCO GI 2021

Study Data Suggest Role for Lenvatinib in Unresectable HCC With Child-Pugh B Liver Function

Victoria Forster, PhD

January 19, 2021

Outcomes of lenvatinib-receiving patients who progressed to Child-Pugh B liver function within the first 8 weeks of treatment were compared with those of patients who maintained Child-Pugh A classification during the same time period.

Investigators compared recurrence-free survival and overall survival outcomes in patients randomly assigned to receive neoadjuvant talimogene laherparepvec (T-VEC) followed by immediate surgery or surgery alone.

Skin Cancer

T-VEC Shows Promise as Neoadjuvant Therapy in Melanoma

Victoria Forster, PhD

January 6, 2021

Investigators compared recurrence-free survival and overall survival outcomes in patients randomly assigned to receive neoadjuvant talimogene laherparepvec (T-VEC) followed by immediate surgery or surgery alone.